AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Nano-X Imaging Ltd.
Video analysis: NNOX
All videosNo video analysis for this stock yet. Request one from our team.
News: NNOX
Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica
Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd.
Nano-X Imaging Ltd. (NNOX) Q2 2026 Earnings Call Transcript
Nano-X Imaging Ltd. (NNOX) Q2 2026 Earnings Call Transcript
Nano-X Imaging Q2 Earnings Call Highlights
Nano-X Imaging NASDAQ: NNOX reported second-quarter 2026 revenue growth driven by its teleradiology, health IT and AI businesses, while recording a substantial non-cash impairment charge and outlining cost-reduction actions intended to extend its cash runway.
Nanox Announces Second Quarter 2026 Financial Results and Provides Business Updates
PETACH TIKVA, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2026, and provided a business update.
Nanox Signs Distribution Agreement with Associated X-Ray Imaging to Expand Nanox.ARC Adoption Across New England
Expands Nanox's growing U.S. distribution network with a leading New England-based medical imaging provider PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-ray, MRI, and CT systems, to support deployment of the Nanox.ARC across the region.
Nanox to Report Second Quarter 2026 Financial Results on September 9, 2026
PETACH TIKVA, Israel, Aug. 25, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2026, before market open on Monday, September, 9, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Guy Nathanzon, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.
Nanox and Vertec Scientific Enter Exclusive Sales Reseller Agreement for the Commercialization of Nanox.AI Bone Solution (HealthOST) in the United Kingdom
Initial three-year term includes minimum annual license commitments PETACH TIKVA, ISRAEL, August 18 2026 -- Nanox Imaging Ltd. (“ Nanox”, or the “Company” NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced its subsidiary, Nanox AI Ltd.
Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd.and Certain Officers – NNOX
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 26-cv-07062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nano-X securities between March 31, 2025 and April 17, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
